Search research articles
Contact Us
Filters
Showing results (181-190 of 330) with videos related to
Page
of 33
Sort By:
The American Journal of Pathology
|
April 17, 2010
Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma
Donna E Hansel, Eric Platt, Mohammed Orloff, et al.
Leukemia & Lymphoma
|
October 21, 2014
Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic anemia
Valeria Visconte, Ali Tabarroki, Christopher J Gerace, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
November 14, 2007
Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy
Dita Gratzinger, Shuchun Zhao, Robert J Tibshirani, et al.
British Journal of Haematology
|
May 17, 2018
JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group
Jason Aynardi, Rashmi Manur, Paul R Hess, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 11, 2017
NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53
Qingqing Cai, Meifeng Tu, Zijun Y Xu-Monette, et al.
Haematologica
|
June 22, 2014
PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin
Sarah L Ondrejka, Armin G Jegalian, Annette S Kim, et al.
Leukemia & Lymphoma
|
May 3, 2008
High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study
Raymond Lai, Nancy L Bartlett, John R Mackey, et al.
Journal of Cancer Research and Clinical Oncology
|
October 18, 2012
Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb
Debra T Chao, Mian Su, Sonia Tanlimco, et al.
Leukemia & Lymphoma
|
August 13, 2009
High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma
Stephen D Smith, Brian J Bolwell, Anjali S Advani, et al.
Cancer
|
June 8, 2019
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance)
Kristie A Blum, Mei-Yin Polley, Sin-Ho Jung, et al.
Page
of 33
Search research articles
Search
Showing results (181-190 of 330) with videos related to
Sort By:
Page
of 33
The American Journal of Pathology
|
April 17, 2010
Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma
Donna E Hansel, Eric Platt, Mohammed Orloff, et al.
Leukemia & Lymphoma
|
October 21, 2014
Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic anemia
Valeria Visconte, Ali Tabarroki, Christopher J Gerace, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
November 14, 2007
Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy
Dita Gratzinger, Shuchun Zhao, Robert J Tibshirani, et al.
British Journal of Haematology
|
May 17, 2018
JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group
Jason Aynardi, Rashmi Manur, Paul R Hess, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 11, 2017
NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53
Qingqing Cai, Meifeng Tu, Zijun Y Xu-Monette, et al.
Haematologica
|
June 22, 2014
PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin
Sarah L Ondrejka, Armin G Jegalian, Annette S Kim, et al.
Leukemia & Lymphoma
|
May 3, 2008
High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study
Raymond Lai, Nancy L Bartlett, John R Mackey, et al.
Journal of Cancer Research and Clinical Oncology
|
October 18, 2012
Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb
Debra T Chao, Mian Su, Sonia Tanlimco, et al.
Leukemia & Lymphoma
|
August 13, 2009
High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma
Stephen D Smith, Brian J Bolwell, Anjali S Advani, et al.
Cancer
|
June 8, 2019
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance)
Kristie A Blum, Mei-Yin Polley, Sin-Ho Jung, et al.
Page
of 33